Want to see CDNA full AI Analyst Report?
CDNA Stock Chart & Stats
$21.42
$0.67(2.95%)
At close: 4:00 PM EST
$21.42
$0.67(2.95%)
Day’s Range― - ―
52-Week Range$11.26 - $40.47
Previous CloseN/A
Volume177.07K
Average Volume (3M)1.03M
Market Cap
$2.05B
Enterprise Value$759.66
Total Cash (Recent Filing)$187.18M
Total Debt (Recent Filing)$24.50M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Jul 30, 2026EPS Estimate
0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding51,659,480
10 Day Avg. Volume1,272,833
30 Day Avg. Volume1,028,733
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.31
Price to Sales (P/S)2.64
P/FCF Ratio27.80
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$36.00Price Target Upside68.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)0.93
Revenue Forecast (FY)$455.93M
Bulls Say, Bears Say
Bulls Say
Cash GenerationCareDx's materially improved operating cash flow and sharply higher free cash flow create durable financial flexibility. Strong cash generation funds buybacks, strategic M&A, and working capital needs, lowering refinancing risk and enabling reinvestment without adding leverage.
Margins And Revenue TractionStable high gross margins (~67%) combined with renewed top-line growth support sustainable operating leverage. Durable margin profile reflects a services-heavy, recurring testing model, which underpins long-term profitability as volumes and digital offerings scale.
Strategic Portfolio RefocusThe divestiture of lower-growth lab products and acquisition of Navaris repositions CareDx toward higher-growth precision testing and oncology. Navaris' clinical evidence and reimbursement profile expand addressable markets and diversify revenue beyond transplant surveillance.
Bears Say
Inconsistent ProfitabilityTrailing profitability remains uneven, with net margins slipping negative despite revenue growth. This inconsistency reduces earnings predictability, weakens returns on equity, and means sustainable GAAP profitability still depends on execution and margin realization over coming quarters.
Elevated Operating Expense BaseA high fixed operating cost structure and recurring bonus accruals materially pressure operating margins. Even with revenue growth, sustaining adjusted EBITDA expansion requires disciplined cost control and productivity gains; otherwise expense inflation can erode cash conversion.
Integration And Timing RiskExecuting the Navaris integration and completing the Lab Products carve-out involve operational, reimbursement and timing uncertainties. Delays or execution shortfalls could disrupt projected cost synergies, revenue recognition, and near-term cash inflows assumed in guidance.
CareDx News
CDNA FAQ
What was CareDx Inc’s price range in the past 12 months?
CareDx Inc lowest stock price was $11.26 and its highest was $40.47 in the past 12 months.
What is CareDx Inc’s market cap?
CareDx Inc’s market cap is $2.05B.
When is CareDx Inc’s upcoming earnings report date?
CareDx Inc’s upcoming earnings report date is Jul 30, 2026 which is in 10 days.
How were CareDx Inc’s earnings last quarter?
CareDx Inc released its earnings results on Apr 28, 2026. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.134 by $0.206.
Is CareDx Inc overvalued?
According to Wall Street analysts CareDx Inc’s price is currently Undervalued.
Does CareDx Inc pay dividends?
CareDx Inc does not currently pay dividends.
What is CareDx Inc’s EPS estimate?
CareDx Inc’s EPS estimate is 0.23.
How many shares outstanding does CareDx Inc have?
CareDx Inc has 51,659,480 shares outstanding.
What happened to CareDx Inc’s price movement after its last earnings report?
CareDx Inc reported an EPS of $0.34 in its last earnings report, beating expectations of $0.134. Following the earnings report the stock price went down -5.066%.
Which hedge fund is a major shareholder of CareDx Inc?
Currently, no hedge funds are holding shares in CDNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CareDx Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$36.00 (68.07% Upside)
$36.00 (68.07% Upside)
Blogger Sentiment
Bearish
CDNA Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 91.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $214.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.3%
Last 30 Days ▲ 14.1%
Last 30 Days ▲ 14.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
236.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-16.05%
Trailing 12-Months
Company Description
CareDx Inc
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
CDNA Stock 12 Month Forecast
Average Price Target
$36.00
▲(68.07% Upside)
Technical Analysis
Ownership Overview
4.41% Insiders
19.86% Mutual Funds
0.21% Other Institutional Investors
53.71% Public Companies and
Individual Investors